Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.57 +0.64 (+1.31%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗

February 04, 2026

Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is...

Via Stocktwits

Topics Intellectual Property

Novo Nordisk Vs Eli Lilly: Which Big Pharma Stock Has More Upside This Year Amid Earnings Season? ↗

February 03, 2026

Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval.

Via Stocktwits

Topics Intellectual Property

Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook ↗

February 03, 2026

Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.

Via The Motley Fool

Topics Initial Public Offering Intellectual Property Stocks

What Drove US Indices Down Today? ↗

February 03, 2026

Investors dumped technology stocks as they move to safer assets like Gold and Silver that rose today.

Via Stocktwits

Topics Artificial Intelligence ETFs Stocks

VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗

February 03, 2026

Via Stocktwits

Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week ↗

January 23, 2026

Via Stocktwits

Novo Nordisk Shares Tumble On Q4 Miss, Weak Sales Forecast And Competition Concerns ↗

February 03, 2026

The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.

Via Stocktwits

The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs

February 02, 2026

As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those...

Via MarketMinute

Topics Economy Government Intellectual Property

Is Novo Nordisk Stock a Bargain Right Now? ↗

February 02, 2026

Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.

Via The Motley Fool

Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? ↗

January 31, 2026

This could finally be the start of the drugmaker's comeback.

Via The Motley Fool

Eli Lilly CEO Sees Medicare Coverage Support Upcoming Obesity Pill Launch: Report ↗

January 30, 2026

CEO Dave Ricks said in an interview with CNBC that many patients are currently paying in cash for the oral obesity drug from rival Novo Nordisk.

Via Stocktwits

Topics Government

Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? ↗

January 30, 2026

Novo Nordisk's weight loss pill could give the company's numbers a big boost this year.

Via The Motley Fool

FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock? ↗

January 30, 2026

The target action date for orforglipron is now April 10.

Via The Motley Fool

2 Beaten-Down Growth Stocks Ready to Bounce Back ↗

January 28, 2026

Both companies are trading at attractive valuations today.

Via The Motley Fool

1 Biotech Stock Set to Rebound in 2026 ↗

January 28, 2026

The Wegovy maker is coming off a dismal showing in 2025, but it's a legitimate 2026 rebound candidate.

Via The Motley Fool

1 Pharmaceutical Stock Set to Rebound in 2026 ↗

January 27, 2026

Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.

Via The Motley Fool

2 Pharmaceutical Stocks Set to Rebound in 2026 ↗

January 27, 2026

There might be massive upside ahead for these drugmakers.

Via The Motley Fool

Where Will Eli Lilly Be in 10 Years? ↗

January 27, 2026

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Via The Motley Fool

Topics ETFs Intellectual Property

Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? ↗

January 26, 2026

Both companies may succeed in this industry.

Via The Motley Fool

Prediction: This Healthcare Stock Could Soar by 40% in 2026 ↗

January 26, 2026

This pharmaceutical giant has recently caught fire, and the stock's run is likely just beginning.

Via The Motley Fool

3 Growth Stocks to Invest $1,000 in Right Now ↗

January 24, 2026

It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments.

Via The Motley Fool

Topics Artificial Intelligence

Should You Dump Eli Lilly's Shares After This Setback? ↗

January 24, 2026

The company got some bad news to start 2026.

Via The Motley Fool

Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly

January 23, 2026

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of...

Via Finterra

Topics Intellectual Property

Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗

January 23, 2026

This biotech has candidates in late-stage clinical development.

Via The Motley Fool

The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era

January 22, 2026

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...

Via MarketMinute

Topics Economy

VIX Tumbles as Trump Rescinds Greenland Tariff Threats

January 22, 2026

Wall Street witnessed a surge in risk-on sentiment today as the Cboe Volatility Index (VIX) fell by over 5%, closing at 15.94. The decline marks a sharp reversal from the "Greenland Chill" that gripped...

Via MarketMinute

Topics Bonds Government Stocks

Arctic Ultimatum: Trump’s Greenland Tariff Threat Triggers $4,700 Gold Surge and 870-Point Dow Plunge

January 21, 2026

The global financial landscape was thrown into chaos on January 20, 2026, as President Donald Trump intensified his administration’s pursuit of Greenland, issuing a sweeping tariff ultimatum against...

Via MarketMinute

Topics Economy Government Stocks

2 Top Stocks to Double Up On Right Now ↗

January 20, 2026

When you find winning stocks, stick with them.

Via The Motley Fool

Topics Artificial Intelligence

Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic ↗

January 20, 2026

Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.

Via Stocktwits

What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? ↗

January 20, 2026

Despite a challenging year, the company has a lot to look forward to in the coming years.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today